Genmab A (GMAB) Other Non-Current Liabilities: 2019-2020
- Genmab A's Other Non-Current Liabilities rose 123.41% to $464,680 in Q4 2020 from the same period last year, while for Dec 2020 it was $464,680, marking a year-over-year increase of 123.41%. This contributed to the annual value of $464,680 for FY2020, which is 99.38% down from last year.
- Latest data reveals that Genmab A reported Other Non-Current Liabilities of $464,680 as of Q4 2020, which was down 100.00% from $118.4 billion recorded in Q2 2020.
- Genmab A's 5-year Other Non-Current Liabilities high stood at $134.2 billion for Q2 2019, and its period low was $207,991 during Q4 2019.
- Over the past 2 years, Genmab A's median Other Non-Current Liabilities value was $59.2 billion (recorded in 2020), while the average stood at $63.2 billion.
- The largest annual percentage gain for Genmab A's Other Non-Current Liabilities in the last 5 years was 123.41% (2020), contrasted with its biggest fall of 11.77% (2020).
- Quarterly analysis of 2 years shows Genmab A's Other Non-Current Liabilities stood at $207,991 in 2019, then soared by 123.41% to $464,680 in 2020.
- Its last three reported values are $464,680 in Q4 2020, $118.4 billion for Q2 2020, and $207,991 during Q4 2019.
